GlassScriptPhysician profile
William D Myers
NPI 1548232440
$4,115.92
in general payments reported to CMS, 2019-2025
40 companies · $572 in 2025
The $572 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $509 · 2021: $994 · 2022: $741 · 2023: $429 · 2024: $546 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,502 · Education: $45.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,501.66 |
| Education | $45.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $486.64 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Abbvie INC. | $345.49 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $313.23 | 2019-2023 | Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals LP | $298.76 | 2019-2024 | Farxiga, Breztri |
| Kowa Pharmaceuticals America, INC. | $298.72 | 2021-2025 | Zoryve, Seglentis |
| Amgen INC. | $296.15 | 2019-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $279.51 | 2021-2025 | Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.81 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $185.36 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $99.08 | 2020-2024 | Ajovy, Austedo Xr |
| Novo Nordisk INC | $96.00 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.85 | 2020-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $81.90 | 2022-2023 | Ongentys, Ingrezza |
| Eisai INC. | $78.05 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.56 | 2025 | Caplyta |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Myers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.